Vaxart oral COVID vaccine produces antibodies in nose and respiratory tissues

Jul. 22, 2022 10:28 AM ETVaxart, Inc. (VXRT)By: Jonathan Block, SA News Editor2 Comments

Close up female doctor with holding medicine Molnupiravir .Coronavirus covid-19 antiviral concept

pcess609/iStock via Getty Images

  • A recent study found that Vaxart's (NASDAQ:VXRT) oral COVID-19 vaccine produced antibodies in the body's mucosal tissues in the nose and lungs as opposed to the bloodstream with currently authorized COVID vaccines.
  • The phase 1

Recommended For You

Comments (2)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.